z-logo
open-access-imgOpen Access
COVID-19 and the Heart and Vasculature
Author(s) -
Bernard Kadosh,
Michael Garshick,
Juan Gaztañaga,
Kathryn J. Moore,
Jonathan Newman,
Michael H. Pillinger,
Ravichandran Ramasamy,
Harmony R. Reynolds,
Binita Shah,
Judith S. Hochman,
Glenn I. Fishman,
Stuart D. Katz
Publication year - 2020
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.120.314513
Subject(s) - covid-19 , pandemic , medicine , disease , psychological intervention , diabetes mellitus , intensive care medicine , translational research , inflammation , obesity , coronavirus , bioinformatics , immunology , infectious disease (medical specialty) , virology , pathology , outbreak , biology , endocrinology , psychiatry
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom